L
Leonard Both
Researcher at St George's, University of London
Publications - 7
Citations - 320
Leonard Both is an academic researcher from St George's, University of London. The author has contributed to research in topics: Rabies virus & Monoclonal antibody. The author has an hindex of 6, co-authored 7 publications receiving 285 citations. Previous affiliations of Leonard Both include Veterinary Laboratories Agency & St George's Hospital.
Papers
More filters
Journal ArticleDOI
Passive immunity in the prevention of rabies
Leonard Both,Leonard Both,Ashley C. Banyard,Craig J. van Dolleweerd,Daniel L. Horton,Daniel L. Horton,Julian K.-C. Ma,Anthony R. Fooks,Anthony R. Fooks +8 more
TL;DR: The advances in passive immunoprophylaxis are discussed, most notably the shift from the recommended polyclonal human or equine immunoglobulins to monoclonal antibody therapies, which might finally become an accessible, affordable, and routinely used part of global health practices for rabies.
Journal ArticleDOI
Monoclonal antibodies for prophylactic and therapeutic use against viral infections
Leonard Both,Ashley C. Banyard,Craig J. van Dolleweerd,Edward Wright,Julian K.-C. Ma,Anthony R. Fooks,Anthony R. Fooks +6 more
TL;DR: Progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable, and this work will help to overcome issues of neutralization escape.
Journal ArticleDOI
Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans
Leonard Both,Craig J. van Dolleweerd,Edward Wright,Ashley C. Banyard,Bianca Bulmer-Thomas,David Selden,Friedrich Altmann,Anthony R. Fooks,Julian K.-C. Ma +8 more
TL;DR: The results provide the molecular rationale for developing 62‐71‐3 mAb for rabies PEP and establish the basis for developing an inexpensive plant‐based antibody product to benefit low‐income families in developing countries.
Journal ArticleDOI
Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody
Craig J. van Dolleweerd,Audrey Y.-H. Teh,Ashley C. Banyard,Leonard Both,Hester C. T. Lotter-Stark,Tsepo L. Tsekoa,Baby Phahladira,Wonderful Shumba,Ereck Chakauya,Claude T. Sabeta,Clemens Gruber,Anthony R. Fooks,Rachel Chikwamba,Julian K.-C. Ma +13 more
TL;DR: A plant-expressed, chimeric antibody was purified and biochemically characterized, and was demonstrated to neutralize rabies virus in a fluorescent antibody virus neutralization assay, and conferred protection in a hamster challenge model.
Journal ArticleDOI
Molecular Pharming: future targets and aspirations.
Mathew J. Paul,Craig J. van Dolleweerd,Pascal M. W. Drake,Rajko Reljic,Harry Thangaraj,Tommaso Barbi,Elena Stylianou,Ilaria Pepponi,Leonard Both,Verena K. Hehle,Luisa De Moraes Madeira,Varghese Inchakalody,Sammy Ho,Thais Guerra,Julian K.-C. Ma +14 more
TL;DR: At St. George’s, molecular Pharming focuses on diseases such as HIV, TB and rabies, and aim to develop production strategies that are simple and potentially easy to transfer to developing countries.